AKTS
Aktis Oncology, Inc.
19.40$
-1.0%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -104.4% | -187.2% | -161.6% | -103.7% | -135.2% | -1,371.8% | -1,208.2% | -1,010.6% | -964.2% | -815.0% | -751.2% | -608.4% | -748.4% | |
| 38.1% | 44.7% | 47.3% | 45.0% | 14.6% | 47.3% | 33.4% | 34.5% | 37.9% | 37.2% | 20.2% | 26.0% | 28.1% | |
| 23.4% | 26.9% | 4.5% | 12.6% | -18.8% | 113.0% | 85.3% | 94.8% | 81.1% | 58.7% | 93.6% | 95.2% | 85.7% | |
| 36.0% | 54.3% | -13.6% | 39.3% | -61.6% | -60.8% | -163.2% | 71.3% | -51.9% | -63.7% | -280.8% | 14.5% | -105.2% | |
| 14.6% | 60.1% | 23.2% | 3.9% | 1.5% | 238.9% | 130.8% | 95.9% | 126.8% | 222.1% | 57.5% | 37.3% | 92.2% | |
| -14.6% | -60.1% | -23.2% | -3.9% | -2.0% | -18,529.7% | – | – | 5,398.0% | -6,762.4% | 636.5% | -7,940.5% | -2,876.6% | |
| 3.3% | – | 0.7% | 138.6% | 190.8% | -193.4% | -32.3% | 0.0% | 1.8% | -41.3% | 10,460.1% | 4.6% | 3,349.5% | |
| -115.7% | -247.3% | -184.0% | 31.0% | -137.2% | -20,094.9% | 1,457.6% | 3,245.8% | 4,435.6% | -7,618.7% | 10,345.4% | -8,544.3% | -275.6% | |
| -119.0% | -247.3% | -184.8% | -107.6% | -137.2% | -1,610.7% | -1,339.0% | -1,106.5% | -1,090.9% | -1,037.2% | -808.7% | -645.7% | -840.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.